OMRON Healthcare Highlights Undiagnosed Heart Failure Risks for Women at ESC 2025 Congress

OMRON Healthcare Co., Ltd., the most recommended blood pressure monitor brand by healthcare professionals worldwide, is set to participate in the ESC Congress 2025 held in Madrid from August 29 to September 1. This major event, organized by the European Society of Cardiology (ESC), brings together healthcare experts to discuss the latest advancements in cardiology.

A Focus on Women's Health

During this year’s congress, OMRON will sponsor a session titled “Unveiling the Hidden Threat: Recognising Undiagnosed Heart Failure in Women.” This critical symposium aims to shed light on the often-overlooked issue of heart failure among women, a demographic that suffers from cardiovascular conditions at alarming rates.

Research shows that cardiovascular issues are the leading cause of death among women globally. However, these conditions are frequently underdiagnosed and undertreated due to longstanding biases in clinical guidelines and symptom recognition. A recent study by OMRON found that while 50% of women reported experiencing concerning symptoms like palpitations and shortness of breath, more than half did not seek medical attention, mistakeing their symptoms for menopause.

Expert Insights

The symposium will feature insights from prominent researchers, including Alta Schutte from the George Institute for Global Health in Australia, Eva Gerdts from the University of Bergen in Norway, and Renate B. Schnabel from the University Heart and Vascular Center in Hamburg, Germany. They will explore topics such as biases in cardiovascular care and the risks associated with female heart failure, underscoring the need for awareness and early detection.

The Role of Technology

OMRON Healthcare emphasizes the importance of regular self-assessment using devices such as their blood pressure monitors, which can connect to the OMRON connect app for data analysis and sharing with healthcare providers. The company believes that this form of home monitoring, coupled with its Intellisense AFib technology to detect atrial fibrillation symptoms, can vastly improve early diagnosis.

In a bid to address these pressing concerns, OMRON will also unveil a new line of arm blood pressure monitors featuring AI-driven algorithms at its booth during the congress. This launch aims to enhance monitoring practices and facilitate better health outcomes for users worldwide.

Looking Ahead

Karen Benegmos-Sanders, General Manager of OMRON Healthcare Europe, expressed excitement about returning to the ESC Congress in Madrid. She stated, “We are thrilled not only to present vital research on women’s cardiovascular health but also to showcase our innovative blood pressure monitoring technology that can lead to improved health outcomes globally.”

This focus on empowering women to take charge of their heart health through education, awareness, and technology reflects OMRON’s commitment to leading the way in preventive healthcare.

Conclusion

As the ESC Congress 2025 approaches, the spotlight remains on the critical health concerns affecting women, particularly undiagnosed heart failure. With groundbreaking research, expert discussions, and innovative product launches, OMRON Healthcare is poised to make a significant impact at this year’s congress.